Comparative Pharmacology
Head-to-head clinical analysis: AMIPAQUE versus CHOLOGRAFIN MEGLUMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIPAQUE versus CHOLOGRAFIN MEGLUMINE.
AMIPAQUE vs CHOLOGRAFIN MEGLUMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrizamide, a non-ionic iodinated contrast agent, attenuates X-rays due to iodine content, enhancing radiographic imaging. It distributes in extracellular fluid and does not cross intact blood-brain barrier; in subarachnoid space, it outlines neural structures.
Cholografin meglumine is an iodinated contrast agent that opacifies the biliary tract. It is actively taken up by hepatocytes and excreted into the bile, allowing radiographic visualization of the bile ducts and gallbladder.
200-300 mg iodine/kg body weight intravenously, maximum 60 g iodine per administration.
Intravenous: 20 mL (10.3 g) of a 52% solution (meglumine salt) administered by slow IV injection over 3-5 minutes; repeated once after 10-15 minutes if visualization is inadequate, not to exceed 40 mL total.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment (up to 20-30 hours in severe renal failure).
Terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic function, reflecting rapid biliary excretion; prolonged in hepatic impairment.
Primarily renal excretion via glomerular filtration; approximately 90-95% of the dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary route.
Primarily hepatic excretion via bile into feces; renal excretion accounts for <1% of the dose in patients with normal hepatic function.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent